{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:12:29Z","timestamp":1779192749914,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007472","name":"UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007472","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jid.2020.05.078","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T02:32:46Z","timestamp":1589596366000},"page":"1681-1687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Meeting Report: The First Global Congress on Epidermolysis Bullosa, EB2020 London: Toward Treatment and Cure"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-8117","authenticated-orcid":false,"given":"Jemima E.","family":"Mellerio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4639-807X","authenticated-orcid":false,"given":"Jouni","family":"Uitto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2020.05.078_bib1","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.jid.2017.05.011","article-title":"Amlexanox enhances premature termination codon read-through in COL7A1 and expression of full length type VII collagen: potential therapy for recessive dystrophic epidermolysis bullosa","volume":"137","author":"Atanasova","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib2","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-18-2661","article-title":"Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma","volume":"25","author":"Atanasova","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2020.05.078_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.omtn.2019.09.009","article-title":"Natural exon skipping sets the stage for exon skipping as therapy for dystrophic epidermolysis bullosa","volume":"18","author":"Bremer","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jid.2020.05.078_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-019-1059-8","article-title":"Occupational therapy for epidermolysis bullosa: clinical practice guidelines","volume":"14","author":"Chan","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2020.05.078_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/13543776.2019.1608181","article-title":"Patent landscape of molecular and cellular targeted therapies for recessive dystrophic epidermolysis bullosa","volume":"29","author":"Dourado Alcorte","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.jid.2020.05.078_bib6","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/bjd.17858","article-title":"Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts","volume":"181","author":"Ebens","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130554","article-title":"Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa","volume":"4","author":"Eichstadt","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2020.05.078_bib8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib9","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/bjd.18559","article-title":"EBGene trial: patient preselection outcomes for the European GENEGRAFT ex\u00a0vivo phase I\/II gene therapy trial for recessive dystrophic epidermolysis bullosa","volume":"182","author":"Gaucher","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.18921","article-title":"Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility [e-pub ahead of print]","author":"Has","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40291-020-00466-7","article-title":"Molecular therapeutics in\u00a0development for epidermolysis bullosa: update 2020","volume":"24","author":"Has","year":"2020","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jid.2020.05.078_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","volume":"551","author":"Hirsch","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jid.2020.05.078_bib13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/bjd.18381","article-title":"Foot care in epidermolysis bullosa: evidence-based guideline","volume":"182","author":"Khan","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib14","doi-asserted-by":"crossref","first-page":"E6536","DOI":"10.1073\/pnas.1803154115","article-title":"Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa","volume":"115","author":"Lincoln","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2020.05.078_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2013.09.041","article-title":"Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI)","volume":"70","author":"Loh","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib16","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.jid.2018.11.036","article-title":"Gene therapy for epidermolysis bullosa","volume":"139","author":"Marinkovich","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13023-019-1086-5","article-title":"Psychosocial recommendations for the care of children and adults with epidermolysis bullosa and their family: evidence based guidelines","volume":"14","author":"Martin","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2020.05.078_bib18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1365-2133.2009.09041.x","article-title":"The Birmingham Epidermolysis Bullosa Severity Score: development and validation","volume":"160","author":"Moss","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib19","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib20","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/exd.13979","article-title":"Epidermolysis bullosa: advances in research and treatment","volume":"28","author":"Prodinger","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib21","article-title":"Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa [e-pub ahead of print]","author":"Rashidghamat","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib22","article-title":"Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study [e-pub ahead of print]","author":"Reimer","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4939-8651-4_2","article-title":"An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases","volume":"1828","author":"Rodrigues","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jid.2020.05.078_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jid.2020.02.032","article-title":"Research Techniques Made Simple: whole-transcriptome sequencing by RNA-Seq for diagnosis of monogenic disorders","volume":"140","author":"Saeidian","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib25","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/bjd.17341","article-title":"Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases","volume":"180","author":"Schr\u00e4der","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/pde.12317","article-title":"Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool","volume":"32","author":"Schwieger-Briel","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib27","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1177\/0963689719857657","article-title":"Collagen VII expression is required in both keratinocytes and fibroblasts for anchoring fibril formation in bilayer engineered skin substitutes","volume":"28","author":"Supp","year":"2019","journal-title":"Cell Transplant"},{"key":"10.1016\/j.jid.2020.05.078_bib28","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/bjd.17943","article-title":"Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa","volume":"181","author":"Twaroski","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib29","doi-asserted-by":"crossref","first-page":"26147","DOI":"10.1073\/pnas.1919347117","article-title":"Toward treatment and cure of epidermolysis bullosa [e-pub ahead of print]","volume":"116","author":"Uitto","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2020.05.078_bib30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/pr.2017.244","article-title":"Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa","volume":"83","author":"Vanden Oever","year":"2018","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jid.2020.05.078_bib31","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/brain\/awx069","article-title":"Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy","volume":"140","author":"von Bischhoffshausen","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.jid.2020.05.078_bib32","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaad.2018.01.019","article-title":"Diacerein orphan drug development for epidermolysis bullosa simplex: a phase 2\/3 randomized, placebo-controlled, double-blind clinical trial","volume":"78","author":"Wally","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.05.078_bib33","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/jid.2013.10","article-title":"Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa","volume":"133","author":"Woodley","year":"2013","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20315736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20315736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:18:13Z","timestamp":1758302293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X20315736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0022202X20315736"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2020.05.078","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meeting Report: The First Global Congress on Epidermolysis Bullosa, EB2020 London: Toward Treatment and Cure","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2020.05.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}